Multiplex Assay Kit for Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay)

CD184; Fusin; NPYR; HSY3RR; LAP3; LCR1; LESTR; NPY3R; NPYRL; WHIM; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide-associated protein 3

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 90-99 93
EDTA plasma(n=5) 96-105 101
heparin plasma(n=5) 78-96 90

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-103% 90-104% 82-99% 90-99%
EDTA plasma(n=5) 88-102% 95-103% 95-102% 89-97%
heparin plasma(n=5) 80-105% 88-101% 98-105% 81-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:CXCR4) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
International Journal of Cancer Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model Wiley: source
Plos one Emodin Suppresses Migration and Invasion through the Modulation of CXCR4 Expression in an Orthotopic Model of Human Hepatocellular Carcinoma PubMed: PMC3589458
Atherosclerosis The non-alcoholic fraction of beer increases stromal cell derived factor 1 and the number of circulating endothelial progenitor cells in high cardiovascular risk subjects: A randomized clinical trial Pubmed:24530788
Pharmacol Rep.? Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression Pubmed:25150002
Pharmacological Reports Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder PubMed: 26481549
Pharmacological Reports A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity Pubmed:27208878
BMC Cancer.  Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists pmc:PMC4866076
Frontiers in Bioengineering and Biotechnology Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison … Pubmed:29670878
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPA940Mu01 Recombinant Chemokine C-X-C-Motif Receptor 4 (CXCR4) Positive Control; Immunogen; SDS-PAGE; WB.
RPA940Mu02 Recombinant Chemokine C-X-C-Motif Receptor 4 (CXCR4) Positive Control; Immunogen; SDS-PAGE; WB.
PAA940Mu02 Polyclonal Antibody to Chemokine C-X-C-Motif Receptor 4 (CXCR4) WB; IHC; ICC; IP.
PAA940Mu01 Polyclonal Antibody to Chemokine C-X-C-Motif Receptor 4 (CXCR4) WB; IHC; ICC; IP.
SEA940Mu ELISA Kit for Chemokine C-X-C-Motif Receptor 4 (CXCR4) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA940Mu Multiplex Assay Kit for Chemokine C-X-C-Motif Receptor 4 (CXCR4) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.